Paperpal Prime Logo

Expert Review of Anticancer Therapy : Impact Factor & More

eISSN: 1744-8328pISSN: 1473-7140

Aims and Scope of Expert Review of Anticancer Therapy

Expert Review of Anticancer Therapy is a monthly peer-reviewed medical journal covering all clinical aspects of cancer therapy. It was established in 2001 and is published by Taylor & Francis under the academic publishing division of Informa. The current Editor-in-Chief is Gertjan J L Kaspers who is Head of Pediatric Oncology at VU University Medical Center Amsterdam. According to Journal Citation Reports, the journal has a 2019 impact factor of 3.573. Less

Key Metrics

CiteScore
6.7
Eigenfactor
0.001 - 0.005
H-Index
79
Impact Factor
< 5
SJR
Q2Oncology
SNIP
1.08
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Expert Review of Anticancer Therapy

Expert Review of Anticancer Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher TAYLOR & FRANCIS LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year2000
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Expert Review of Anticancer Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Expert Review of Anticancer Therapy

RTsDEN: reverse task attention enabled deep learning model for lung cancer detection using computed tomography
  • 2 Nov 2026
  • Expert Review of Anticancer Therapy
The dual role of Schlafen11 in brain tumors: Jekyll and Hyde
  • 2 Nov 2026
  • Expert Review of Anticancer Therapy
Barriers to the use of brachytherapy for treatment of cervical cancer and prostate cancer in low- and middle-income countries
  • 3 Oct 2026
  • Expert Review of Anticancer Therapy
Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state of the art
  • 3 Oct 2026
  • Expert Review of Anticancer Therapy
Angiosarcoma: adaptive designs leveraging vascular biology and antiangiogenic repurposing
  • 9 Aug 2026
  • Expert Review of Anticancer Therapy
The burden of acute myeloid leukemia: an integrated review of clinical, economic, and patient-centered evidence
  • 7 Aug 2026
  • Expert Review of Anticancer Therapy
RTsDEN: reverse task attention enabled deep learning model for lung cancer detection using computed tomography
  • 2 Nov 2026
  • Expert Review of Anticancer Therapy
The dual role of Schlafen11 in brain tumors: Jekyll and Hyde
  • 2 Nov 2026
  • Expert Review of Anticancer Therapy
Barriers to the use of brachytherapy for treatment of cervical cancer and prostate cancer in low- and middle-income countries
  • 3 Oct 2026
  • Expert Review of Anticancer Therapy
Bladder-preserving trimodality therapy for muscle-invasive bladder cancer: current state of the art
  • 3 Oct 2026
  • Expert Review of Anticancer Therapy
Angiosarcoma: adaptive designs leveraging vascular biology and antiangiogenic repurposing
  • 9 Aug 2026
  • Expert Review of Anticancer Therapy
The burden of acute myeloid leukemia: an integrated review of clinical, economic, and patient-centered evidence
  • 7 Aug 2026
  • Expert Review of Anticancer Therapy

FAQs on Expert Review of Anticancer Therapy